Lung Non-Small Cell Carcinoma

In this phase 1, open-label, dose-escalation trial, 81 patients with NSCLC involving an EGFR exon 20 insertion in phase 2 of the study were administered 1,050 mg amivantamab (1,400 mg if > 80 kg) give… (full text at CIViC)

PMID 34339292 · Park et al., 2021 · Open in CIViC

In this phase 3 trial, 308 patients with NSCLC harbouring EGFR exon 20 insertions were treated with a combination of amivantamab and chemotherapy (carboplatin-pemetrexed) [n = 153] or chemotherapy alo… (full text at CIViC)

PMID 37870976 · Zhou et al., 2023 · Open in CIViC

A retrospective study showed that out of 11 patients with stage IV lung adenocarcinoma treated with erlotinib who carried in-frame exon 20 insertion variant, only 3 patients showed objective response … (full text at CIViC)

PMID 26096453 · Naidoo et al., 2015 · Open in CIViC

In retrospective analysis of clinical trials and case studies, most patients with EGFR exon 20 insertion mutations did not benefit from first-generation EGFR kinase inhibitors.

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In stage IV lung adenocarcinoma patients (n=2) harboring EGFR inframe exon 20 insertion mutation, EGFR exon 20 insertion was associated with progressive disease after 1 and 3 months of erlotinib monot… (full text at CIViC)

PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC

A 78 year old M former smoker with lung adenocarcinoma with no prior therapy was tested for mutation in EGFR exons 18 to 21 and had Exon 20 in frame insertion. He had a three month course of first gen… (full text at CIViC)

PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC

In this open-label phase1/2 trial, 114 patients with EGFR exon 20 insertion NSCLC who were previously treated with platinum received 160 mg mobocertinib once daily. The primary endpoint was confirmed … (full text at CIViC)

PMID 34647988 · Zhou et al., 2021 · Open in CIViC

Retrospective study of six Chinese patients with EGFR exon 20 insertion mutant stage IV non-small cell lung carcinoma treated with osimertinib. Four of the patients experienced partial response (67.7%… (full text at CIViC)

PMID 31208370 · Fang et al., 2019 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

This is a phase I/II study patients with NSCLC received TAK-288. In patients with EGFR exon 20 insertions, 24 patients who received 80 - 160 mg total daily dose showed ORR of 39% and DCR of 94%.

Open in CIViC

A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

Double blind Phase II clinical trial evaluated 208 patients for efficacy of gefitinib against non-small cell lung cancer. For individuals taking 250mg/day, they observed an objective response rate of … (full text at CIViC)

PMID 12748244 · Fukuoka et al., 2003 · Open in CIViC

A single case with EGFR(ex24)::FGFR1(ex10) was identified in a large study of 3505 EGFR(del19, L858R, G719*, S768I, and L851Q)-positive NSCLC cases. The goal of the study was to analyze the role of co… (full text at CIViC)

PMID 29883838 · Schrock et al., 2018 · Open in CIViC

In this phase 2 study, 129 patients with NSCLC, including those with less common, non-resistant EGFR mutations such as S768I, L861Q, and/or G719X, were treated with afatinib in two cohorts: 99 with a … (full text at CIViC)

PMID 22452895 · Yang et al., 2012 · Open in CIViC

In a meta-analysis of 7 clinical trials of erlotinib (some vs placebo or other treatment), 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved p… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In a study of 889 non-small cell lung cancer patients, mutations in the EGFR gene was observed in 11.1% of patients (58 of 518 sequenced). Patients with an EGFR mutation were associated with an improv… (full text at CIViC)

PMID 20493771 · Cappuzzo et al., 2010 · Open in CIViC

3 patients with stage IV non small cell lung adenocarcinoma with G719A mutation were given erlotinib. 1 patient was alive at end of study with progression free survival (PFS) of 27.2 months and overal… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Patient with E709K and G719A demontrates PR and an early … (full text at CIViC)

PMID 25179728 · Chang et al., 2015 · Open in CIViC

A 60-year old man (smoker: 300 pack-years) presented with lung adenocarcinoma measuring 3.0 x 2.3 cm and multiple lymph node metastases. Next-generation sequencing revealed a EGFR G719A (abundance 5.0… (full text at CIViC)

PMID 30922580 · Zeng et al., 2019 · Open in CIViC

A patient with stage IV lung squamous cell carcinoma harboring an EGFR G719C mutation and high PD-L1 expression (tumor proportion score of 90%) experienced disease progression after 1.5 months of afat… (full text at CIViC)

PMID 40959071 · Fu et al., 2025 · Open in CIViC

The E709A+G719C double mutation was found in an 80-year-old female never smoker with advanced adenocarcinoma of the lung with acinar and BAC characteristics. Erlotinib was given at the starting dose o… (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have G719D mutation and were treated with the 1st generation TKIs gefiti… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

The G719S mutation was found in a 50-year-old female never smoker with advanced adenocarcinoma of the lung. One month after the end of chemotherapy, , she started erlotinib at 150 mg/d. At the first c… (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

In an advanced lung adenocarcinoma patient harboring EGFR G719S mutation, EGFR G719S was reported to be sensitive to erlotinib treatment. The patient was initially treated with standard chemotherapy, … (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

Study found somatic EGFR mutations localized to exons 19,21 in 8/9 patients who exhibited a response to Gefitinib treatment. Of these mutations 7/8 were localized near the ATP cleft Gefitinib targets,… (full text at CIViC)

PMID 15118073 · Lynch et al., 2004 · Open in CIViC

A 58-year-old male with stage IVB lung adenocarcinoma presented with respiratory symptoms and widespread metastases. NGS revealed EGFR-GNAT3 fusion (EGFR exons 1–24 to GNAT3 exon 8; 76.3% abundance) a… (full text at CIViC)

PMID 38595815 · Wang et al., 2024 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

A 74 year old female former smoker with 8 pack years and EGFR H773_V774insH lung adenocarcinoma patient was given erlotinib as second line treatment, and had progressive disease as best response with … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

The del I744_K745insKIPVAI mutation was found in a 36-year-old former female smoker, with an adenocarcinoma of the lung. She received erlotinib at a 150 mg daily dose. A clinical meaningful improvemen… (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was tre… (full text at CIViC)

PMID 27569104 · Kocoglu et al., 2016 · Open in CIViC

In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (4… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib. The pati… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC